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Empirical Evidence on Structural
Takeover Defenses:
Where Do We Stand?
JOHN C. COATES IV*
Structural takeover defenses' (such as poison pills2 and staggered
boards3) have long been controversial. One reason for the controversy is
a striking split between legal academics and legal practitioners in how
defenses are viewed. Legal academics generally have taken a dim view
of takeover defenses, while legal practitioners have generally supported
defenses in the advice they give to clients and in public policy debates.
Academic hostility to defenses has been built in large part on the
common belief that defenses reduce firm value, a view that is thought to
be supported by both economic theory and empirical evidence. The the-
ory of how defenses reduce firm value represents a simple application of
agency cost analysis: agency costs make defense adoption possible and
likely, and defenses increase agency costs by making it harder for princi-
pals (shareholders) to replace, or otherwise discipline, agents (directors)
through a takeover. I will have little to say about this theory, other than
to note here that it remains to be seen whether it is possible to develop a
* Assistant Professor of Law, Harvard Law School; B.A., 1986, University of Virginia;
J.D., 1989 New York University Law School. My thanks to Yakov Amihud, Lucian Bebchuk,
David Charny, Michele Cotton, Rob Daines, Ron Gilson, Jeff Gordon, Jack Jacobs, Marcel
Kahan, Louis Kaplow, Mike Klausner, Martin Lipton, Eric Robinson, and Roberta Romano for
comments on earlier versions of this or closely related papers, and to participants at the Fourth
Annual Institute on Mergers & Acquisitions, sponsored by the University of Miami School of
Law. The usual disclaimer applies.
1. A note on terminology: Two types of defenses may be distinguished: (1) transactional
defenses, which are financial or operational transactions anticipating or reacting to a bid and
designed to make a takeover more difficult, by raising a firm's share price, paying off the bidder,
or reducing a bidder's profit; and (2) structural defenses, which are legal terms or mechanisms,
often adopted in advance of a bid, designed to deter or impede bids without having a financial or
operational effect on the target. This paper focuses on structural defenses, but for brevity it refers
to "defenses" as short-hand for structural defenses. A class of structural defenses not addressed is
that of multiple classes of voting equity. Such structures are qualitatively different, in that they
generally are adopted not to deter or impede bids, but to prevent them altogether, and so allow the
sale of equity without loss of a control "lock."
2. See Wachtell, Lipton, Rosen & Katz, The Share Purchase Rights Plans, in RONALD J.
GILSON & BERNARD S. BLACK, THE LAW AND FINANCE OF CORPORATE AcQuIsITIONs 4-12 (2d ed.
1998 Supp.) (setting forth terms of standard rights plan).
3. Firm with staggered boards elect a portion (usually one third) of their directors each year,
with directors serving multi-year (usually three) terms. See DEL. CODE ANN. 8 § 141(d) (1974)
(Supp. 1998) (authorizing staggered boards with two or three classes having two- or three-year
terms).
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general and consistent theory of the firm to explain observed ownership
and control structures in the United States.
The focus of my comments, however, is the way in which empirical
studies have reinforced the academic conviction that agency cost theory
is the lens through which to view takeover defenses. It has been widely
believed by academics and others that those studies show stock prices
for firms fall on average when firms adopt defenses such as poison pills.
Without that empirical evidence, the theoretical case against defenses
remains important and useful, but much less compelling, particularly
when policy must be made.4
Practitioner support for defenses undoubtedly stems in part from
the fact that defense adoption (and litigation over defenses) provides
practitioners with profits. Yet, practitioners have also looked to eco-
nomic theory and empirical evidence for support when convincing
boards of directors that adopting defenses is justified and in persuading
courts not to intervene against defenses. The evidence in favor of
defenses has been produced for the most part not by academics, but by
investment banks and proxy solicitors. It generally shows that defenses
such as poison pills increase premiums that target firm shareholders
receive in takeovers. This evidence is consistent with the theory that
well-motivated or adequately constrained boards will use defenses not to
entrench themselves or defeat advantageous takeover bids, but to bar-
gain for target shareholders and extract a greater share of deal synergies
than they might otherwise be able to do.
Recently, both academics and practitioners have been confronted
with a new source of evidence on takeover defenses, and the results are
decidedly mixed, supporting neither groups' view with certainty. Three
recent and ongoing studies show that prior to initial public offerings
(IPOs) a significant number of firms adopted terms making takeovers
more difficult than does default law. This seems to fly in the face of the
4. This is a summary version of a more comprehensive critical review of the empirical
literature on takeover defenses that is available at <http://www.ssrn.com> [hereinafter Coates,
Critique], and is part of a series of related papers on takeover defenses after 1990. Other papers in
the series include John C. Coates IV, Measuring the Domain of Mediating Hierarchy: How
Contestable Are U.S. Public Corporations?, 24 J. CORP. L. 837 (1999); John C. Coates IV, An
Index of the Contestability of Corporate Control: Studying Variation in Takeover Vulnerability
(June 30, 1999) (unpublished manuscript on file with author) (describing new methodology for
studying takeover defenses and other governance terms that attempts to address shortcomings of
prior empirical studies of defenses) [hereinafter Coates, Studying Variation]; John C. Coates IV,
Failure in the Market for Corporate Legal Advice: Explaining Variation in Takeover Defenses in
IPOs 1990-1992, (unpublished manuscript on file with author) (applying new methodology to
defenses adopted in initial public offerings in the period 1990-1992) [hereinafter, Coates,
Explaining Variation]. In the interest of full disclosure, it should be noted that I was formerly a
partner at the law firm of Wachtell, Lipton, Rosen & Katz, which is generally credited with
inventing the best-known takeover defense, the poison pill.
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academic belief that defenses reduce firm value.' Yet, the same research
shows that defenses vary significantly, contrary to the typical practi-
tioner's belief that a full set of defenses is privately optimal for all
firms.6 These surprising and mixed results make a reassessment of prior
empirical evidence on takeover defenses worthwhile, both to examine
the methodologies used, and to assess the strength of support such evi-
dence provides for the opposing academic and practitioner positions on
takeover defenses.
I will summarize the two most prominent types of empirical studies
of structural defenses (poison pill "event studies" and poison pill pre-
mium studies) in order to assess whether there is an empirical basis
either for the academic view that defenses reduce firm value or for the
practitioner view that pills increase firm value.' This critique shows
that, contrary to the views of either camp, such studies do not provide
strong support either for opposing or supporting takeover defenses.
Event studies of defenses, even taken at face value, produce weak and
inconsistent results. More importantly, they are premised on the incor-
rect assumption that pill adoption changes the takeover defense posture
of the adopting firm and fail to take into account ways that pills and
other structural defenses interact. This failure on the part of event stud-
5. See Robert Dairies & Michael Klausner, Value-Maximizing Charters: An Empirical
Analysis of Antitakeover Provisions in Corporate Charters at the IPO Stage, (Jan. 13, 1997)
(unpublished manuscript on file with author); L. Field, Control Considerations of Newly Public
Firms: The Implementation of Antitakeover Provisions and Dual Class Shares Before the IPO
(Feb. 19, 1999) (unpublished manuscript on file with author) (finding that 50% of industrial firms
going public 1988-1992 either use dual class structures or more than one takeover defense at time
of IPO). In related work, I study governance terms adopted by firms going public in the period
1990-1992. John C. Coates IV, Explaining Variation, supra note 4.
6. See Michael Tognetti, Anti-Takeover Defenses and Share Value: An Interview of the
Industry, (Apr. 14, 1999) (unpublished manuscript on file with author) (documenting consistent
and general belief among practitioners that takeover defenses are advisable generally and prior to
an IPO). Defenses that are privately optimal may not be socially optimal, if inter alia they involve
externalities. See LUCIAN A. BEBCHUK & LUIoI ZINGALES, CORPORATE OWNERSHIP STRUCTURES:
PRIVATE VERSUS SOCIAL OPnMALTrrY (John M. Olin Center for Law, Economics, and Business,
Harvard Law School Discussion Paper No. 181, 1996).
7. See generally FRANK EASTERBROOK & DANIEL FISCHEL, THE ECONOMIC STRUCTURE OF
CORPORATE LAW 204 (1991); Ronald J. Gilson, The Case Against Shark Repellent Amendments:
Structural Limitations on the Enabling Concept, 34 STAN. L. RaV. 775, 804 n. 110 (1982); DALE
ARTHUR OsTERLE, THE LAW OF MERGERS, AcQuIsrrIONS, AND REORGANIZATIONS 468 (1991)
("available data ... suggest [that] when a firm employs ... defenses before a ... bid is on the
table, the announcement . . . reduces the value of the firm's stock"); ROBERTA ROMANO, THE
GEaNIUS OF AMERICAN CORPORATE LAW 70-71 (1993); Jeffrey G. Macintosh, The Poison Pill: A
Noxious Nostrum for Canadian Shareholders, 15 CAN. Bus. L.J. 276, 282 (1988) (surveying
empirical evidence on use of poison pills in the U.S.). But see JEssE H. CHOPER, JOHN C. COFFEE,
JR., & RONALD J. GILSON, CASES AND MATERIALS ON CORPORATIONS 907-09 (4th ed. 1995)
("evidence seems reasonably clear that successful resistance for the target is bad news for
shareholders, but the evidence is much more ambiguous regarding the impact of specific defensive
tactics," including adoption of poison pills and other structural defenses).
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ies greatly reduces their ability to reveal wealth effects of defenses.
While pill premium studies have produced results that are stronger and
more consistent than those produced by pill event studies, the same
flaws afflict premium studies. Thus, although the results of premium
studies are interesting and worthy of further analysis, they do not, on
their own, provide good evidence that defenses improve firm value, as
practitioners sometimes claim. In sum, prior empirical studies of take-
over defenses do not support the belief that defenses either increase or
decrease firm value on average.
Finally, I conclude with a brief discussion of the implications of
this critical review of empirical studies of defenses, for academics, prac-
titioners, and courts.
I. EVENT STUDIES BY THEIR OWN TERMS TELL US
LITTLE ABOUT DEFENSES
Until recently, empirical research on takeover defenses has cen-
tered on event studies of poison pills.8 It is fair to say that event studies
have provided the principal evidence supporting legal academic views of
the effects of defenses on shareholder wealth and social welfare.9 Eas-
terbrook & Fischel rely on such studies as the primary evidence for
asserting that "[e]very device giving managers the power to delay or
prevent an acquisition makes shareholders worse off."' Romano states
8. Event study methodology is now well-known and generally accepted as providing
potentially useful information about the wealth effects of legal and other "events" affecting stock
prices. See John J. Binder, Measuring the Effects of Regulation with Stock Price Data, 16 RAND J.
ECON. 167 (1985); Stephen J. Brown & Jerold B. Warner, Using Daily Stock Returns: The Case
of Event Studies, 14 J. FiN. ECON. 3 (1985); Eugene F. Fama, L. Fisher, Michael C. Jensen &
Richard Roll, The Adjustment of Stock Prices to New Information, 10 INT'L ECON. REV. 1 (1969);
G. William Schwert, Using Financial Data to Measure Effects of Regulation, 24 J.L. & ECON. 121
(1981). A succinct and basic description of techniques for measuring abnormal returns more
generally is contained in J. FRED WESTON, KwANo S. CHUNG, & JUAN A. Siu, TAKEOVERS,
RESTRUCTURING AND CORPORATE GOVERNANCE 93-106 (2d ed. 1998).
9. Parallel to event studies of pills are event studies of midstream antitakeover charter
amendments (ATAs), often called "shark repellents," but the results of ATA studies are even less
conclusive than pill studies. See, e.g., Weston et al., supra note 8, at 423-24 (reviewing event
studies and concurring in characterization of ATAs as "nonevents"). Another set of event studies
that bears on takeover defenses are studies of state anti-takeover statutes. For a survey of such
studies and a general discussion of such statutes, see ROBERTA ROMANO, THE GENIUS OF
AMERICAN CORPORATE LAW 60-75 (1993). See also John C. Coates IV, State Takeover Statutes
and Corporate Theory: The Revival of an Old Debate, 64 N.Y.U. L. REV. 806 (1989) (describing
and evaluating such statutes in light of theories of the corporation).
10. EASTERBROOK & FISCHEL, supra note 7, at 204 (emphasis in original); see also id., at 196-
98 (summarizing event studies listed in id., at 209-11), and at 205 (citing "the absence of any
existing [takeover defense] that increases targets' market value" after reviewing event studies)
(emphasis in original). Many economists also were convinced by event studies, see, e.g., ROBERT
BRUNER, THE POISON PILL ANTI-TAKEOVER DEFENSE: THE PRICE OF STRATEGIC DETERRENCE 21
(1991) (touting event studies as evidence of wealth effects of pills); PAUL MILGROM & JOHN
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that "event studies of defensive tactics find significant negative returns
on their adoption"" and cites those studies to support the statement that
poison pills "are most likely to defeat [takeover] bids and, therefore, to
diminish shareholder wealth."
' 12
Even taken at face value,13 however, pill event studies produced
little reliable evidence on the wealth effects of takeover defenses.
Within a given study, results are mixed and weak; between studies,
results are inconsistent; over time, results have become less significant
(both statistically and economically); and when firms are partitioned on
various traits, results differ among subsamples. Even with no further
analysis, event studies do not provide much, if any, support for theoreti-
cal (positive) arguments that such defenses harm shareholders for nor-
mative arguments that such defenses should be prohibited. Furthermore,
they do not provide any assistance in understanding how defenses might
improve firm value, or improve firm value at some firms and not at
others. Thus, they cast little light on why some, but not all, firms adopt
defenses prior to IPOs.
The most well-known and frequently cited event studies of take-
over defenses use public announcement of the adoption of a poison pill
as the "event" to study. Jarrell & Ryngaert led the way with a 1986
study of 245 pills, published with the imprimatur of the SEC's Office of
the Chief Economist. Yet, their general results were that in the two days
following announcement of pill adoption, stock prices of adopting com-
panies fell on average, net of market movements, only by an absolutely
small amount (0.22%) not statistically different from zero.' 4 Even after
ROBERTS, ECONOMICS, ORGANIZATION AND MANAGEMENT 182-83 (1992) (citing review of event
studies as "empirical evidence" that "adopting a poison pill typically reduces the firm's share
value," representing "simply an expropriation of the shareholders' property"); J. FRED WESTON,
KWANG S. CHUNG & JUAN A. SIU, MERGERS, RESTRUCTURING, AND CORPORATE CONTROL ch.20
(1990) (concluding that poison pills harm shareholder wealth based on event studies). Some have
been more careful of late, see, e.g., Weston, et al, supra note 8, at 423-24 (favorably summarizing
Robert Comment & G. William Schwert, Poison or Placebo? Evidence on the Deterrence and
Wealth Effects of Modem Antitakeover Measures, 39 J. FIN. ECON. 3 (1995), as finding pills
achieve some takeover deterrence but "target shareholders gain[ ] even after taking into account
deals ... not completed because of poison pills"); but not all, see, e.g., Chamu Sundaramurthy,
Corporate Governance Within the Context of Antitakeover Provisions, 17 STRATEGIC MGT. J. 377,
380 (1996) (stating that "preponderance of empirical research supports the managerial
entrenchment viewpoint derived from agency theory") (after reviewing event studies).
11. ROMANO, supra note 7, at 70-71 (comparing event studies of takeover defenses with event
studies of state anti-takeover statutes).
12. Id. at 80 & n.58 (contrasting purportedly less detrimental effects of golden parachutes and
greenmail) (emphasis added).
13. Event studies are subject to a number of potential methodological flaws many of which
have not been adequately addressed in event studies of takeover defenses. See generally GILsON
& BLACK, supra note 2, at 215-28.
14. Gregg Jarrell and Michael Ryngaert, Office of Chief Economist of the Securities and
20001
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the authors focused on a relatively tiny (n=15) subsample, they were
only able to find a relatively modest impact (-2.21%).5 By compari-
son, merger premiums averaged 42% over pre-bid market prices in the
1980s,16 and premiums in hostile takeovers typically were larger than
premiums in negotiated deals. 7 Not every firm adopting a pill would
receive such a premium price, but the odds should have been high for
firms in their sub sample, which was limited to only firms subject to
takeover speculation. If pills substantially impaired the likelihood that
target shareholders would receive 50% premiums (as claimed by the
authors), a price decline at a carefully selected group of likely targets
should have been greater than 2.21%.
In sum, the results of the first serious event study of poison pills
were statistically mixed and economically weak.'" Even if the samples
used were representative, the wealth effects of pills were found to be
neither large, nor certain, nor general. Nevertheless, the authors felt able
to conclude that "poison pills are harmful to shareholders, on net,' '19 a
mischaracterization (or at least an exaggeration 20 ) common to the early
pill studies that has been parroted ever since.2'
Exchange Commission, The Effects of Poison Pills on the Wealth of Target Shareholders (Oct. 23,
1986).
15. The authors appear to have chosen pill adoptions in ways that appear ad hoc and may well
have biased their results.
16. Defined as the percent premium offered for a controlling equity interest (acquisitions of
51% or more of a company's outstanding shares), measured against market price 30 days prior to
announcement. See MERGERSTAT REVIEW 1990.
17. See Jarrell, Brickley & Netter, The Market for Corporate Control: The Empirical
Evidence Since 1980, 2 J. EcON. PERSP. 49, 49 (1988).
18. Cf. Maclntosh, supra note 7, at 284 (noting that results of early event studies of pills are
"quite small" but arguing that "any negative price effect" shows that pills should not be adopted)
(emphasis in original).
19. Jarrell & Ryngaert, supra note 14, at 43. Their conclusion was also based on a study of
thirty takeover battles involving pills, in which 45% of the companies remained independent,
resulting in short-term price declines. Another 45% of the companies were acquired at higher
prices resulting from auctions. Net, targets experienced a weighted average net-of-market return
over six months of -2.0%. See id. at 25-28. These results, again, do not support any strong or
general view for or against pills.
20. Jarrell overstated the findings of his own study, claiming (in a 1987 study of ATAs) that
his poison pill study found that "on average, 245 poison pills issued from 1981 through 1986 [had]
a negative effect on stock prices of -1.7% at their announcement." Jarrell & Poulsen, Shark
Repellents and Poison Pills: Stockholder Protection - From the Good Guys or the Bad Guys?, 4
MIDLAND CORP. FIN. J. 39, 128 (1986). In fact, his pill study found no statistically significant
average effect, and found the 1.7% effect only with respect to 37 pills (both flip-over and flip-in)
at companies that were subject to takeover speculation but were involved in no "confounding
event" in announcing their pills. Jarrell & Ryngaert, supra note 14, tbl. 9.
21. See, e.g., EASTERBROOK & FiSCHEL,. supra note 10, at 204; Melvin Aron Eisenberg,
Contractual Freedom in Corporate Law: Articles & Comments; The Structure Of Corporation
Law, 89 COLUM. L. REv. 1461, 1503 n.197 (1989) (citing Jarrell & Ryngaert study); Matthew
Garms, Shareholder By-law Amendments and the Poison Pill: The Market for Corporate Control
and Economic Efficiency, 24 J. CORP. L. 433, 449 n.172 (1999) (citing Jarrell & Ryngaert, and
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Since 1986, the majority of poison pill event studies have followed
Jarrell & Ryngaert in attempting to resolve the debate over pills' wealth
effects.22 Subsequent studies make the case against pills look even
weaker. Results have been sensitive to event intervals, and the majority
of studies show no significant price effect unless some attempt is made
to isolate a subsample of pills, either by focusing on firms subject to
takeover bids, as done by Jarrell & Ryngaert, or by focusing on some
other firm characteristic, such as the number of independent directors or
pills adopted in a particular year. Pooling results from full samples in all
studies using two or three-day event intervals, the weighted average
price reaction is +0.02%.23 The net price impact of pill adoptions has
been positive, albeit close to zero.
The net results of pill studies has also been two orders of magnitude
smaller than two or three-day price effects of secondary stock offerings
(-3.0%),24 announcements of acquisitions (abnormal returns ranging
from -1.2% to -3.3%),25 spin-offs (+3.4%),26 deaths of inside 5+%
Malatesta & Walkling studies; citing Malatesta & Walking as supportive of a conclusion that the
"adoption of poison pills has a negative effect on shareholder wealth"); Ronald J. Gilson &
Reinier Kraakman, Delaware's Intermediate Standard for Defensive Tactics: Is There Substance
to Proportionality Review?, 44 Bus. LAW. 247, 264 n.59 (1989), (citing Jarrell & Ryngaert study);
SAMuEL C. THOMPSON, JR., BusINEss PLANNING FOR MERGERS AND ACQUISITIONS 1081 (1997),
(reprinting excerpt from Jarrell & Ryngaert study).
22. See James A. Brickley, Jeffrey L. Coles & Rory L. Terry, Outside Directors and the
Adoption of Poison Pills, 35 J. FIN. EcON. 371 (1994); Dosoung Choi, Sreenivas Kamma &
Joseph Weintrop, The Delaware Courts, Poison Pills, and Shareholders Wealth, 5 J.L. EcON. &
ORG. 375 (1989); Robert Comment & G. William Schwert, Poison or Placebo? Evidence on the
Deterrence and Wealth Effects of Modem Antitakeover Measures, 39 J. FIN. ECoN. 3 (1995);
Sudip Datta & Mai Iskandar-Datta, Takeover Defenses and Wealth Effects on Securityholders:
Poison Pills of Poison Pill Adoptions, 20 J. BANKING & FIN. 1231 (1996); Paul H. Malatesta &
Ralph A. Walking, Poison Pill Securities: Stockholder Wealth, Profitability, and Ownership
Structure, 20 J. FIN EcON. 347 (1988); Michael Ryngaert, The Effect of Poison Pill Securities on
Shareholders Wealth, 20 J. FIN. ECON. 377 (1988).
23. In doing this, I follow Michael C. Jensen & Richard S. Ruback, The Market for Corporate
Control: The Scientific Evidence, 11 J. FIN. EcON. 5, 12-13 tbl. 3 n.h (1980) (pooling results from
several studies of abnormal returns associated with mergers and tender offers). As with their
pooling of results, abnormal returns are weighted by samples in calculating the weighted average,
and no effort has been made to adjust for overlap in the samples. If one sets statistically
insignificant results to zero, the pooled result is -0.04%. For just studies that excluded
"confounding events," the weighted average is -0.62%.
24. See R. BREALEY & S. MYERS, PRINCIPLES OF CORPORATE FINANCE 421 (6th ed. 2000)
(summarizing general findings of studies); R. BREALEY & S. MYERS, PRINCIPLES OF CORPORATE
FINANCE 349 n.21 (4th ed. 1991) (summarizing three studies).
25. See MARK L. SIROWER, THE SYNERGY TRAP: How COMPANIES LOSE THE ACQuIsmON
GAME 147 tbl.A. 1 (1997) (surveying results from ten studies, including six using two or three-day
event intervals around merger announcements). The public policy reaction to these findings,
among legal academics and more generally, has been much more muted compared to the much
weaker findings on takeover defenses.
26. See LANE DALEY, VIKAS MEHROTRA, & RANJINI SIVAKKUMAR, Corporate Focus and
Value Creation: Evidence from Spinoffs, 45 J. FIN. EcON. 257 tbl.2 (1997).
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blockholders (+3.01%),27 and sales of 5+% blocks of stock (+5.1%),28
and much smaller even than effects of non-binding agreements to make
relatively minor governance reforms, such as the adoption of confiden-
tial voting (+0.90%).29
Needless to say, legal academics have not taken nearly as strong a
position, if any, on these other types of corporate events as they have on
takeover defenses, despite stronger empirical evidence suggesting that
these events have a bigger impact on shareholder wealth. Legal academ-
ics have not, for example, suggested a block dispersion rule for large
blockholders, despite evidence showing that such a rule would on aver-
age have more than double the effect of a rule against pills.
II. DESIGN FLAWS OF EVENT STUDIES
Given the dominant academic theory that poison pills represent and
are enabled by, a form of agency cost, the non-findings of the poison pill
event studies are puzzling. Why do poison pill adoptions fail to reduce
share prices? One answer is that agency cost theory is not the whole
story. Upon critical reflection, it seems more likely that pill event stud-
ies suffer from serious design flaws that explain why they produced such
unexciting results. By the same token, these methodological flaws also
make pill event studies problematic for positive research and nearly use-
less for normative or policy analysis.
Two previously unnoticed design flaws are as follows. 30 First, pill
adoption rarely has any real effect on the takeover defense posture of the
firm adopting a pill. Pill adoption, per se, is simply unimportant from a
takeover defense perspective. Second, structural defenses interact. As a
result, they cannot be assessed by studying them in isolation. In fact,
their interaction is more important than any given defense on its own.
A. Pill Adoptions Rarely Have Any Effect; Pill Potential
Is All That Matters
The principal design flaw of pill event studies is that they treat the
decision to adopt - or to not adopt - a pill as an important event, when it
is, in fact, not an important event.
27. See MYRON B. SLOVIN & MARIE E. SUSHKA, Ownership Concentration, Corporate
Control Activity, and Firm Value: Evidence from the Death of Inside Blockholders, 48 J. FIN.
1293 tbl. 11 (1993).
28. See MICHAEL J. BARCLAY & CLIFFORD G. HOLDERNESS, Negotiated Block Trades and
Corporate Control, 46 J. FIN. 861 tbl. 11 (1991).
29. See DEON STRICKLAND, KENNETH W. WILES & MARC ZENNER, A Requiem for the USA:
Is Small Shareholder Monitoring Effective?, 40 J. FIN. ECON. 319 tbl. 5 (1996).
30. For a longer discussion of these flaws and a discussion of other design flaws or other
shortcomings of the defense studies see Coates, Critique, supra note 4.
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To see this, note that a company that declines to adopt a pill at time
t can always adopt one at time t+1 or t+2. Likewise, a firm adopting a
pill at time t can eliminate (redeem) it at time t+1 or t+2. Pill adoption
at time t is completely and almost instantaneously reversible at times
t+1 and t+2. For large sophisticated firms the reversal (adoption or
redemption) can occur in a single business day.3" For less sophisticated
firms, takeover bids are subject to sufficient delay under both the Wil-
liams Act and the Hart-Scott-Rodino Antitrust Improvements Act, that a
target firm will rarely if ever be prejudiced by failing to adopt a pill in
advance.32
No additional deterrence is achieved by virtue of the pill being
adopted at time t or t+1, except to the extent that adoption sends signals
about management's readiness and intention to resist a takeover. No
additional barganing power is achieved by adopting a pill a time t or t
+1, except for such signal effects. Thus, the adoption of a pill at t does
not generally change the legal takeover vulnerability of the adopting
firm.
To be clear, the point is not that pills have no effect on bids.
Rather, it is that pill adoptions by particular firms rarely have (non-sig-
nal) effects on bids because of the possibility of later adoption. Thus, it
is the potential for the pill that achieves the great bulk of the pill's deter-
rent effect, to the extent it has one. Once the Delaware Supreme Court
made it clear in Moran v. Household International33 that pills were legit-
imate to adopt, all Delaware firms (except those few with other govern-
ance terms that would impede pill adoption) have had a "shadow pill" in
place. Takeovers of such firms have thus been restrained by a set of
"shadow restrictions" (the expectation of a pill's adoption and subse-
quent effects) on transfer of control to a hostile bidder.34 Whether or not
the potential for pills has had an impact on bids remains open, precisely
because the studies of defenses have not taken the "shadow pill" into
account."
31. The only legal action necessary for either step is a board meeting and approval. Lawyers
can keep necessary documents ready and directors can meet by conference call on several hours
notice.
32. See 15 U.S.C. § 18a (1999) (Hart-Scott-Rodino Antitrust Improvements Act of 1976); 15
U.S.C. §§ 78m(d)-(e), 78n(d)-(f) (1999) (Williams Act). Comment & Schwert make this point,
supra note 22, but they do not fully realize its import for interpreting event studies.
33. 490 A.2d 1059 (Del. Ch. 1985), affd, 500 A.2d 1346 (Del. 1985).
34. Moran, 490 A.2d at 1082.
35. See Ryngaert, supra note 22, and Malatesta & Walkling, supra note 22. Both works
attempted to measure price reactions to Delaware court decisions upholding the Household
decision. Malatesta & Walkling find no significant reaction for Household itself after either the
Chancery Court or Delaware Supreme Court decisions in Household, nor did they find a
significant reaction for firms with pills involved in other takeover fights at the time the decisions
were announced. Id. at 364 tbl. 4. One explanation is simply that even the potential for pills is
2000]
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Another way to see the point is to ask whether a rational, well-
advised bidder would view a takeover target as any more vulnerable to
takeover as a result of having not yet adopted a pill. Given how easily
and often pills are adopted by targets once bids have been made, the
answer is clearly "no." As a result, a firm that has adopted a pill is in
nearly the same takeover posture as a firm that has not yet adopted a
pill. 36 If that is true, the adoption of a pill cannot be expected to gener-
ate any significant price reactions related to the pill itself. Any price
reaction to pill adoptions reflects one thing only - inferences about
private information in the hands of managers of adopting companies.
B. Defenses Interact and Should Not Be Studied Separately
Studies of structural takeover defenses suffer from a second, poten-
tially more significant, flaw.37 The simple point is that defenses interact.
One term can dramatically impact the effect of another term. A short
example, focusing on what are probably the two most important struc-
not important. Another explanation is that, although it is true that the court in Moran v.
Household upheld the adoption of a (flip-over) pill, it did so by deferring any decision about how
pills could be "used" by targets (i.e., whether fiduciary duties might ever require target directors to
redeem a pill in the face of a bid), and only upheld the adoption per se. See also Stahl v. Apple
Bancorp, Inc., Fed. Sec. L. Rep. (CCH) 95,412 (Del. Ch. Aug. 9, 1990) (holding that use, not
adoption, is critical factor in deciding pill's legality; use of pill to block revocable proxies would
be illegal, but use of pill to block irrevocable proxies or voting agreements was legal). In fact, no
Delaware court has ever squarely addressed either the question of whether a discriminatory flip-in
pill, now standard, is legal to adopt (although the reasoning in Household does not distinguish
between types of pills) or the question of whether a target board can "just say no" and use a pill to
block a hostile tender offer without doing more (although it is widely considered to be highly
likely that Delaware courts would, on a good record, uphold such a defense). See, e.g., Jeffrey
Gordon, Corporations, Markets and the Courts, 91 COLUM. L. REV. 1931, 1944-45 (1991);
Lyman Johnson & David Millon, The Case Beyond Time, 45 Bus. LAW. 2105 (1990); see also
Moore v. Wallace Computer Services, Inc., 898 F. Supp 1089 (D. Del. 1995). In other words,
there has never been a precise moment in the development of Delaware law that could be isolated
as the "event" that resolved the legality of the standard pill in its full operation.
36. Targets in several of the hostile bids during the 1990s did not have poison pills until after
a hostile bidder emerged, and yet each was able to adopt a pill and prevent the bidders from
acquiring the target without going through a proxy contest. See, e.g., Bill Atkinson, Glen Burnie
Bancorp Tries to Resist Hostile Takeover, BALTtMORE SUN, Feb. 8, 1998, at 3C (Glen Burnie
adopts pill in response to hostile bid); Urocor Rejects Dianon's Acquisition Advances, MED.
INDUSTRY TODAY, Aug. 21, 1998, available in LEXIS/New S Library (UroCor adopted pill after it
received hostile bid); Geraldine Fabrikant, The Media Business: A Defense by Time Warner, N.Y.
TimEs, Jan. 21, 1994, at DI (after Seagram Co.'s announcement that it intended to buy up to 15%
of Time-Warner, Inc.'s stock spurred speculation that Seagram might make a hostile bid for Time-
Warner, Time-Warner adopted a rights plan, which it previously had not done as part of a
shareholder relations campaign).
37. A few pill event studies attempt to examine interactions between takeover defenses, but
none arrived at useful results, in large part, because the studies reflect no theory about ways in
which defenses could interact, and why. For example, Jarrell & Ryngaert, supra note 22, at 30,
Ryngaert, supra note 22, at 22, and Choi et al., supra note 22 (finding no correlation between
price reactions of pill adoptions by companies with and without various charter provisions).
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tural defenses, pills and staggered boards, should illustrate the point.38
Suppose Firm A has adopted a pill and Firm B has not. Firm A has
a staggered board and Firm B does not. Initially, note the way in which
the pill and the staggered board interact. Without the pill, the presence
or absence of a staggered board is largely irrelevant because a tender
offer or open-market accumulations of stock will allow a bidder to
acquire control of the target in approximately one month, the minimum
time necessary to clear antitrust review and for tender offers to comply
with the Williams Act. The target board can (in theory) refuse to resign
after the control acquisition has occurred, but it almost never will do so,
for reasons discussed by Ron Gilson over 15 years ago. 9 Indeed, this
was largely the reason that the pill was invented.
With the pill, the staggered board becomes a far more effective
defense than the pill alone because a pill can always be removed by the
target board. Thus, a bidder always has the option of removing the tar-
get board in a proxy fight. If a target's directors are all up for election
each year, the pill can be removed in no more, and often much less, than
a year from the bid's initiation. In contrast, if the target has a staggered
board, the pill is protected for at least, and often much more, than one
year. For firms with pills, effective staggered boards change a maximum
time required to take over the target to the minimum time required.
Nearly all studies of defenses have assumed that Firm A, with a pill
and a staggered board, is less vulnerable to takeover than Firm B. Sup-
pose, however, that Firm A permits shareholders to remove directors
without cause and Firm B does not, and neither has a provision that
prohibits the adoption of pills or allows shareholders to act by written
consent or call a special meeting. Now the legal takeover vulnerability
of both firms is identical.
Because Firm B can adopt a pill at any time, the presence of a pill
at Firm A and the absence of a pill at Firm B are irrelevant to bid out-
comes (and, thus, signal effects aside, bid incidence). Likewise, given
the ability of shareholders to remove directors without cause at Firm A,
its staggered board is ineffective. Shareholders at both firms are in a
position to mobilize, or to be mobilized by a bidder, and to replace the
entire board at the next annual meeting. At Firm B, directors are nor-
mally up for election at the next annual meeting. At Firm A, sharehold-
ers (or a bidder) can remove all directors, and fill the resulting
vacancies. Thus, traditional studies would misgauge the relative take-
38. I take up the question of term interactions at length and in detail in a separate paper. See
Coates, Studying Variation, supra note 4. A full discussion of the ways in which governance
terms interact is beyond the scope of this paper
39. See Gilson, supra note 7 (discussing ineffectiveness of staggered board absent a pill).
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over vulnerability of firms A and B because traditional studies assume
that pills and staggered boards affect takeover vulnerability, when often
they do not. These interactions are common and have significant effects
on nearly a third of public firms sampled.4°
III. PREMIUM STUDIES
A second set of empirical studies on defenses - "premium studies" -
have produced results that are stronger and more consistent than those
produce by pill event studies. However, the flaws that afflict poison pill
event studies afflict premium studies as well. Although the results of
premium studies are interesting and worthy of further analysis, they do
not provide good evidence that defenses improve firm value, as practi-
tioners have sometimes claimed.
Georgeson & Co. has over the years conducted a number of studies
of the relationship between pills and takeover premiums. Its first
study,4" published at the height of public policy debate over takeovers
and defenses, was controversial. 42 The principal substantive finding that
firms with pills receive larger than average takeover premiums, has
however, held up over time. Georgeson emphasized that, unlike event
studies, its study measured actual economic effects, rather than "only
investor perceptions of pills." As Georgeson noted, pills were relatively
new during the period reflected in early event studies.43
In 1995, J.P. Morgan & Co. updated and confirmed the basic find-
ings of these earlier studies.4" They examined all acquisitions over $500
million of a majority interest of U.S. companies from 1988 to 1995
(n=245) and found that premiums paid to firms with pills were 51.4%
over market price five days prior to the initial offer. Firms without pills
received an average premium of only 35.5%. Similar results were found
when J.P. Morgan examined various partitions, including hostile and
friendly offers, deals under and over $1 billion, deals involving cash,
40. See Coates, Studying Variation, supra note 4.
41. See Georgeson & Company Inc., Poison Pill Impact Study (Mar. 31, 1988) [hereinafter
Study 1]; see also Georgeson & Company Inc., Poison Pill Impact Study II (Oct. 31, 1988)
(hereinafter Study 11].
42. In part, controversy arose because Georgeson & Co. was assisted in the study by Martin
Lipton, who is generally credited with having invented the poison pill. See Jarrell & Ryngaert,
supra note 22, at 1 n. 1.; J.E. Heard, Poison Pill Study Lambasted, 16 Pensions and Investment Age
34, 34, (Apr. 18, 1988), cited in Robert F. Bruner, supra note 10, at 21. In addition, some
participants doubted the Georgeson results because Georgeson "usually serv[es] defenders in
takeover battles." Bruner, supra note 10, at 19.
43. See Study II, supra note 41, at 1 (preface).
44. See J.P. Morgan & Co., Poison Pills and Acquisition Premiums (Dec. 18, 1995)
(unpublished study on file with author); see also Donald G. Margotta, Takeover Premiums: With




stock or mixed consideration, and deals in 1988, 1989, 1994 and 1995.
In all cases, firms with pills received significantly higher premiums than
firms without pills. A 1997 update of this study reached identical con-
clusions for all transactions (n=300) in which a majority interest of a
U.S. public firm was purchased from 1993 through June 1997.4"
Notwithstanding the consistency and impressiveness of these
results, studies showing that pills and deal premiums correlate are a clas-
sic example of correlation not proving causation. None of the studies
offers any explanation of how pills cause higher premiums. In fact, pills
cannot have such an effect except in rare instances. Nearly all bidders
will assume a target of a hostile bid will adopt a pill once the bid is
launched, assuming that resistance may attract alternative bidders or
impose delay in developing a transactional defense for the target. If bid-
ders presume that all targets will adopt pills, then the prior adoption of a
pill has no causal connection to premiums offered in the hostile bid. As
with the event studies, none of the pill premium studies attempt to sepa-
rate pills that are adopted specifically to enhance the target's bargaining
power from those that were previously adopted but had no direct role in
the takeover fight.
Correlation without causation is most clearly seen in the studies of
negotiated (i.e., non-hostile) deals, which also show a correlation
between pills and higher premiums. Even if some purportedly friendly
deals are in fact quasi-hostile, the vast majority of friendly deals are not.
Without any description of a causal mechanism, the fact that pills corre-
late with higher premiums is not persuasive evidence that pills cause
higher premiums. The fact that such a correlation exists for friendly
deals (albeit slightly less strong) suggests that the pill/premium correla-
tion arises from some source other than the real effects of a pill.
The correlation between bid premiums and pills is largely, if not
entirely, caused by something not included in the regressions used to
produce these results. Any number of possibilities exist: firms may
adopt pills because of concerns that stock prices do not match firm
45. See KENNETH A. BERTSCH, POISON PILLS, INVESTOR RESPONSIBILITY RESEARCH CENTER,
CORPORATE GOVERNANCE SERIES 1998 BACKGROUND REPORT E at 21, (Jun. 25, 1998),
(summarizing update). Similar results were found in a 1997 Georgeson-sponsored study by Jamil
Aboumeri. The study can be found on Georgeson & Co. Inc.'s web page (http://georgeson.com),
and it is summarized in Poison Pills and Shareholder Value 1992-96, 68 Aspen Law and Business
Corporation No. 24 (Dec. 15, 1997) (also on file with author). Aboumeri noted several ways in
which acquired firms with pills differed from those without: they were larger (based on market
capitalization), had lower price-to-book ratios and were more frequently acquired in hostile rather
than friendly deals. Aboumeri noted that premiums also varied with size and hostility: higher
premiums are paid for smaller firms and in hostile deals. Still, after controlling for all three
factors, Aboumeri finds that firms with pills received statistically significant higher premiums on
average than firms without pills.
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value, or because stock prices of such firms are more volatile than stock
prices generally. Such firms may be harder to value without private
information and may attract higher premiums (which are measured
against pre-bid market prices). Perhaps managers of firms that adopt
pills are in industry sectors that have more competitors, or in consolidat-
ing sectors where deal activity is already quite high for other reasons. In
either instance, bid premiums might be higher than average for the same
reasons (competition or consolidation creating more auctions). Or per-
haps such firms are more apt to adopt "best practices" and adopt pills
because 50+% of the Fortune 500 has done so. Such firms may be more
apt to adapt best practices elsewhere in their management and opera-
tions, including negotiation strategies, resulting in higher premiums.
Alternatively, perhaps firms that adopt pills do so for reasons such as
entrenchment and agency cost, traditionally attributed to managers,
causing a stock price decline that is reversed by hostile bids, resulting in
high premiums. Whereas, firms that do not adopt pills are already so
well managed that any premiums paid in hostile or friendly bids are only
based on operational synergies and not on the elimination of such
agency costs. Whatever the effective cause of higher premiums, the
presence or absence of pills is not likely to be the answer, any more than
the wealth effects of pills is the explanation for price reactions to their
adoptions.
CONCLUSION
Despite the fact that no studies have shown any strong or consistent
price reactions to pill adoptions, and no result remotely close to that
predicted by an agency cost theory of managerial entrenchment, pill
event studies published in the mid-1980s have set the tone for all subse-
quent academic discourse on the topic. Event studies of defenses were
seriously flawed in ways that have gone unnoticed: pill adoptions are
wrongly assumed to have a direct impact on legal takeover vulnerability,
and no study has adequately taken account of the ways that defenses
interact. The general failure of researchers to find strong or consistent
relationships between defense adoptions and price reactions is, in hind-
sight, not surprising. These flaws also have afflicted non-event studies.
Although pills appear to consistently have a strong correlation with
higher premiums for target firms, the correlation probably masks some
other currently unproven cause rather than the effect of pills.
This largely critical review of the scientific evidence on takeover
defenses leaves academics with the task of correcting or at least taking
into account research flaws identified in this paper. Researchers need to
recognize that, based on the scientific evidence produced to date, pill
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adoption cannot proxy for "management entrenchment." For the same
reason, pill adoption cannot proxy for "majority rule for takeover bids"
or "higher extraction of surplus," as the pill premium studies might sug-
gest. That leaves less direct, but potentially more productive, research
methods. The search for scientific evidence of the wealth effects of
defenses should shift from pills to "hard-wired" defenses, such as char-
ter provisions, that cannot easily be changed after ownership is dis-
persed. Models, built on case studies and field research, of the way in
which defenses affect takeovers need to be created and used.46 Relation-
ships between firm traits and defenses adopted prior to IPOs should be
explored. The results should be compared to mature firms distribution
of defenses, to explore the possibility that defenses are generally effi-
cient, or efficient for some subset of firms.
It is important for practitioners, and other informational
intermediaries' advising boards or investors, that both constituencies
understand the limitations of the empirical research done to date on
defenses. Institutional shareholders should be altered to the fact that at
least half of the traditional academic case against defenses stands on
shaky ground. Accordingly, shareholders should be more careful about
adopting uniform voting policies hostile to defenses. Boards, however,
should not be permitted to rely, without caveat, on pill premium studies
to support a decision to adopt or not adopt a pill at a given point in time.
Finally, Delaware courts should take some comfort from the fact
that they resisted strong academic arguments and political efforts that
attempted to push them to dramatically repudiate pills and other struc-
tural defenses. The empirical case against defenses remains unproven,
and, without empirical support, the theoretical case against defenses is
not as compelling as it might have seemed to hostile commentators fol-
lowing cases such as Paramount Communications, Inc. v. Time Inc.47
Delaware's chancellors and justices have moved carefully and incre-
mentally in responding to both takeovers and takeover defenses, this
conservative approach is in keeping with the traditions of the common
law and has proven sound. The failure of empirical studies to ade-
quately document the predictions of agency cost theory may turn out to
be a failure of empirical methodologies, and the case against defenses
may be resuscitated, or it may turn out to reflect an imaginative failure
on the part of legal and economic theoreticians to see beyond the simple
and intuitively compelling aspects of agency cost theory.
46. Such a model is presented in Coates, Studying Variation, supra note 4.
47. 571 A.2d 1140 (Del. 1989).
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